Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$3.20 USD
+0.06 (1.91%)
Updated Sep 11, 2024 01:47 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
LSTA 3.20 +0.06(1.91%)
Will LSTA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LSTA
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
Other News for LSTA
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
Lisata Therapeutics? Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Lisata Therapeutics granted FDA Orphan Drug Designation for certepetide
Lisata jumps on FDA orphan drug status for liver cancer drug
Lisata Therapeutics: Strong Buy Rating on Robust Financials and Promising Clinical Trials